Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens: A new approach for diagnosis of malignant disease

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 145-154

  Yepes, Diego ^a   Jacob, Anette ^b   Dauber, Marc ^b   Costina, Victor ^a   Hofheinz, Ralf ^c   Neumaier, Michael ^a   Findeisen, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; Mass spectrometry; Peptide library; Protease profiling; Reporter peptides; Serum

Indexed keywords

ASPARAGINE; ASPARTIC ACID; BLOOD CLOTTING FACTOR 10; CANCER PROCOAGULANT; CYSTEINE PROTEINASE; GELATINASE A; MATRILYSIN; PROTEINASE; SYNTHETIC PEPTIDE; TUMOR MARKER;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; COLORECTAL TUMOR; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; INCUBATION TIME; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; RECEIVER OPERATING CHARACTERISTIC; REPORTER GENE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; HT29 CELLS; HUMANS; KINETICS; NEOPLASMS; PEPTIDE HYDROLASES; PEPTIDE LIBRARY; PEPTIDES; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTRATE SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79955985810     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1009     Document Type: Article

References (41)

1. Lopez-Otin C and Bond JS: Proteases: multifunctional enzymes in life and disease. J Biol Chem 283: 30433-30437, 2008.
2. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
3. Gocheva V, Wang HW, Gadea BB, et al: IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24: 241-255, 2010.
4. Findeisen P, Peccerella T, Post S, Wenz F and Neumaier M: Spiking of serum specimens with exogenous reporter peptides for mass spectrometry based protease profiling as diagnostic tool. Rapid Commun Mass Spectrom 22: 1223-1229, 2008. (Pubitemid 351600772)
5. Villanueva J, Nazarian A, Lawlor K and Tempst P: Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat Protoc 4: 1167-1183, 2009.
6. Peccerella T, Lukan N, Hofheinz R, et al: Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. Clin Chem 56: 272-280, 2010.
7. Dekker LJ, Burgers PC, Charif H, et al: Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases. Proteomics 10: 2348-2358, 2010.
8. Somiari SB, Somiari RI, Heckman CM, et al: Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 119: 1403-1411, 2006. (Pubitemid 44258818)
9. Wildes D and Wells JA: Sampling the N-terminal proteome of human blood. Proc Natl Acad Sci USA 107: 4561-4566, 2010.
10. Rawlings ND, Morton FR, Kok CY, Kong J and Barrett AJ: MEROPS: the peptidase database. Nucleic Acids Res 36: D320-D325, 2008. (Pubitemid 351149743)
11. Witt I: Test systems with synthetic peptide substrates in haemostaseology. Eur J Clin Chem Clin Biochem 29: 355-374, 1991.
12. Findeisen P, Post S, Wenz F and Neumaier M: Addition of exogenous reporter peptides to serum samples before mass spectrometry-based protease profiling provides advantages over profiling of endogenous peptides. Clin Chem 53: 1864-1866, 2007.
13. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ and Tempst P: A sequence-specific exopeptidase activity test (SSEAT) for 'functional' biomarker discovery. Mol Cell Proteomics 7: 509-518, 2008.
14. Tempst P: Response to 'Letter to the Editor' by Diamandis ER Kulasingam V and Sardana G. J Clin Invest eletter: http://www.jci.org/eletters/view/26022, 2006.
15. Schneider EL and Craik CS: Positional scanning synthetic combinatorial libraries for substrate profiling. Methods Mol Biol 539: 59-78, 2009.
16. Schechter I and Berger A: On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27: 157-162, 1967.
17. Lin TS, Chiou SH, Wang LS, et al: Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep 12: 717-723, 2004.
18. Xia Z, Xing Y, So MK, Koh AL, Sinclair R and Rao J: Multiplex detection of protease activity with quantum dot nanosensors prepared by intein-mediated specific bioconjugation. Anal Chem 80: 8649-8655, 2008.
19. Beyer M, Nesterov A, Block I, et al: Combinatorial synthesis of peptide arrays onto a microchip. Science 318: 1888, 2007.
20. Mielicki WP: Biochemistry of cancer procoagulant. Haemostasis 31 (Suppl 1): 8-10, 2001.
21. Matharoo-Ball B, Ratcliffe L, Lancashire L, et al: Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach. Proteomics Clin Appl 1: 605-620, 2007.
22. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P and Witten IH: The WEKA Data Mining Software: An Update; SIGKDD Explorations. Vol. 1, Issue 1, 2009.
23. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998. (Pubitemid 29003722)
24. Amirkhosravi A, Biggerstaff JP, Warnes G, Francis DA and Francis JL: Determination of tumor cell procoagulant activity by Sonoclot analysis in whole blood. Thromb Res 84: 323-332, 1996. (Pubitemid 26417644)
25. Volmer MW, Stuhler K, Zapatka M, et al: Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 5: 2587-2601, 2005. (Pubitemid 40966486)
26. Kozlov IA, Melnyk PC, Hachmann JP, et al: A high-complexity multiplexed solution-phase assay for profiling protease activity on microarrays. Comb Chem High Throughput Screen 11: 24-35, 2008.
27. Backes BJ, Harris JL, Leonetti F, Craik CS and Ellman JA: Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nat Biotechnol 18: 187-193, 2000. (Pubitemid 30091180)
28. Furlong ST, Mauger RC, Strimpler AM, Liu YP, Morris FX and Edwards PD: Synthesis and physical characterization of a P1 arginine combinatorial library, and its application to the determination of the substrate specificity of serine peptidases. Bioorg Med Chem 10: 3637-3647, 2002.
29. Mielicki WP, Mielicka E and Gordon SG: Cancer procoagulant activity studies using synthetic peptidyl substrates. Thromb Res 87: 251-256, 1997. (Pubitemid 27355997)
30. Betts MJ and Russell RB (eds): Amino acid properties and consequences of subsitutions. In: Bioinformatics for Geneticists. Wiley, New Jersey, pp289-316, 2003.
31. Sharony R, Yu PJ, Park J, Galloway AC, Mignatti P and Pintucci G: Protein targets of inflammatory serine proteases and cardiovascular disease. J Inflamm 7: 1-17, 2010.
32. Consolo M, Amoroso A, Spandidos DA and Mazzarino MC: Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med 24: 143-152, 2009.
33. Gordon SG and Cross BA: An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res 50: 6229-6234, 1990. (Pubitemid 20323679)
34. Orme NM, Fletcher JG, Siddiki HA, et al: Incidental findings in imaging research: evaluating incidence, benefit, and burden. Arch Intern Med 170: 1525-1532, 2010.
35. Bok RA, Hansell EJ, Nguyen TP, Greenberg NM, McKerrow JH and Shuman MA: Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis 6: 272-280, 2003. (Pubitemid 38088188)
36. Faraggi D and Kramar A: Methodological issues associated with tumor marker development. Biostatistical aspects. Urol Oncol 5: 211-213, 2000.
37. Mischak H, Apweiler R, Banks R, et al: Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl 1: 148-156, 2007.
38. Schlosser G, Pocsfalvi G, Huszar E, Malorni A and Hudecz F: MALDI-TOF mass spectrometry of a combinatorial peptide library: effect of matrix composition on signal suppression. J Mass Spectrom 40: 1590-1594, 2005. (Pubitemid 43048629)
39. Szajli E, Feher T and Medzihradszky KF: Investigating the quantitative nature of MALDI-TOF MS. Mol Cell Proteomics 7: 2410-2418, 2008.
40. Kuzyk MA, Smith D, Yang J, et al: Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 8: 1860-1877, 2009.
41. Crooks GE, Hon G, Chandonia JM and Brenner SE: WebLogo: a sequence logo generator. Genome Res 14: 1188-1190, 2004.